AI Visualize debuted its cloud-based artificial intelligence (AI) image analysis and viewing software at RSNA 2017 in Chicago.
The software uses deep-learning algorithms to assess imaging data for diagnostically valuable information that is not apparent through conventional analysis, and it transmits detailed 3D/2D renderings to users on any internet-enabled device. It supports x-ray, ultrasound, CT, MRI, 3D tomosynthesis, and digital pathology images.
The AI software processes images in the AI VoXcell cloud using graphics processing unit technology. It streams information and imaging tools to users, wherever located, in real-time, and it uses predictive buffering. Server-side rendering eliminates the need for onsite graphics processors, supporting off-the-shelf supercomputing infrastructure, the company noted.
The software has 11 international patents, received U.S. Food and Drug Administration (FDA) clearance, and is HIPAA-compliant.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
